Opexa to Present at the Rodman & Renshaw 15th Annual Global Investment Conference

  Opexa to Present at the Rodman & Renshaw 15th Annual Global Investment
  Conference

Rodman & Renshaw Global Investment Conference 2013

Business Wire

THE WOODLANDS, Texas -- September 5, 2013

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing
Tcelna^®, a patient-specific T-cell immunotherapy for the treatment of
multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s President
and Chief Executive Officer, will deliver a corporate presentation at the
Rodman & Renshaw Annual Global Investment Conference. The conference will be
held September 8-10^th at The Millennium Broadway Hotel in New York City.

Opexa’s presentation will occur at 2:50 p.m. (EDT) on Tuesday, September 10,
2013 in Room 7.04 of The Millennium Broadway Hotel and will include an
overview of the Company’s ongoing clinical development program for Tcelna, the
Company’s lead therapy for MS. The presentation will be webcast and the link
to access the audio webcast and presentation will be available on the Investor
Relations page of the Company’s website at www.opexatherapeutics.com.

About Opexa

Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning
the interests of patients, employees and shareholders. The Company’s leading
therapy candidate, Tcelna^®, is a personalized T-cell immunotherapy currently
in a Phase IIb clinical development program (the Abili-T trial) for the
treatment of Secondary Progressive Multiple Sclerosis. Tcelna is derived from
T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and
reintroduced into the patients via subcutaneous injections. This process
triggers a potent immune response against specific subsets of autoreactive
T-cells known to attack myelin.

About Multiple Sclerosis (MS)

Multiple Sclerosis is a chronic, inflammatory condition of the central nervous
system and is the most common, non-traumatic, disabling neurological disease
in young adults. It is estimated that approximately two million people have MS
worldwide.

While symptoms can vary, the most common symptoms of MS include blurred
vision, numbness or tingling in the limbs and problems with strength and
coordination. The relapsing forms of MS are the most common. The Secondary
Progressive form of MS represents about a third of the MS patient population.

For more information visit the Opexa Therapeutics website at
www.opexatherapeutics.com.

About Tcelna

Tcelna is a potential personalized therapy that is under development to be
specifically tailored to each patient's disease profile. Tcelna is
manufactured using ImmPath™, Opexa's proprietary method for the production of
a patient-specific T-cell immunotherapy, which encompasses the collection of
blood from the MS patient, isolation of peripheral blood mononuclear cells,
generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised
against selected peptides from myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the
return of these expanded, irradiated T-cells back to the patient. These
attenuated T-cells are reintroduced into the patient via subcutaneous
injection to trigger a therapeutic immune system response.

Opexa is currently conducting a Phase IIb study of Tcelna. Named “Abili-T,”
the trial is a randomized, double-blind, placebo-controlled clinical study in
patients who demonstrate evidence of disease progression with or without
associated relapses. The trial is expected to enroll 180 patients at
approximately 30 leading clinical sites in the U.S. and Canada with each
patient receiving two annual courses of Tcelna treatment consisting of five
subcutaneous injections per year. The trial’s primary efficacy outcome is the
percentage of brain volume change (atrophy) at 24 months. Study investigators
will also measure several important secondary outcomes commonly associated
with MS, including disease progression as measured by the Expanded Disability
Status Scale (EDSS), annualized relapse rate and changes in disability as
measured by EDSS and the MS Functional Composite.

Contact:

Company
Karthik Radhakrishnan
Opexa Therapeutics, Inc.
Chief Financial Officer
281-775-0600
kradhakrishnan@opexatherapeutics.com
or
Investor Relations
Adam Cutler
The Trout Group
Adam Cutler
646-378-2936
opexa@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.